Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche consolidates mGluR5 antagonist position with Seaside alliance for autism

This article was originally published in Scrip

Executive Summary

Roche has strengthened its mGluR5 antagonist portfolio by entering a collaboration with Seaside Therapeutics. Seaside will license its patents covering the use of mGluR5 antagonists for the treatment of neurodevelopmental disorders exclusively to Roche. Roche will pursue these compounds for the treatment of fragile X syndrome (FXS) and autism spectrum disorders (ASD). Seaside's mGluR5 antagonist assets include STX107, which completed a Phase I study for FXS in 2010 but has been sitting on the backburner while the company focuses on its GABA-B agonist programme.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts